An umbrella review published in Diabetes, Obesity & Metabolism reports that adding GLP-1 receptor agonists to insulin therapy in type 1 diabetes was associated with modest HbA1c reductions and clinically relevant weight loss, alongside sharply higher rates of gastrointestinal side effects.

GLP-1 receptor agonists are the drug class that includes semaglutide and liraglutide, approved for type 2 diabetes and obesity rather than type 1. An umbrella review is a review of reviews: instead of pooling trials directly, the authors gathered 18 systematic reviews with meta-analyses covering 56 unique primary studies, 35 of them randomized controlled trials, and reanalyzed the underlying data themselves.

The overlap problem

The interesting methodological move here is that the authors measured how much the existing reviews were recycling the same trials. The corrected covered area came out at 19.6 percent, which they call a very high degree of overlap, driven largely by two studies: ADJUNCT ONE and ADJUNCT TWO.

That matters because a field with 18 meta-analyses sitting on top of essentially the same two big trials looks better evidenced than it is. Counting reviews is not the same as counting evidence, and this paper is one of the few to say so with a number attached.

Key results

Adjunctive GLP-1RA therapy reduced HbA1c by 0.23 percent (95% CI, -0.30 to -0.17) and body weight by 3.93 kg (-4.29 to -3.56), both rated moderate certainty, along with a 5.74 IU per day reduction in total daily insulin at low certainty. Time in range did not improve significantly: a mean difference of 1.99 percent with a confidence interval crossing zero, at very low certainty.

On safety, nausea rose with a risk ratio of 2.88 (2.20-3.76), vomiting 3.11 (1.94-4.97), and withdrawal due to adverse events 2.10 (1.42-3.12), all at high certainty. Severe hypoglycemia and diabetic ketoacidosis showed no statistically significant increase, but both estimates were low certainty with wide intervals.

Limitations

The certainty ratings do most of the talking: the insulin-dose and safety findings are low certainty, and the time-in-range result is very low. Twenty-one of the 56 included primary studies were nonrandomized, and the authors describe the underlying evidence base as methodologically heterogeneous with variable certainty.

Bottom line

The authors conclude these findings do not support routine use, but suggest a potential role in selected individuals for whom weight reduction and lower insulin requirements are therapeutic priorities. What remains unsettled is whether ketoacidosis risk is genuinely flat or simply understudied.